CLDN6、TRIM59、CMTM6在鼻咽癌组织中的表达及临床意义

doi:10.11958/20242041

天津医药 ›› 2025, Vol. 53 ›› Issue (3): 272-276.doi: 10.11958/20242041

CLDN6、TRIM59、CMTM6在鼻咽癌组织中的表达及临床意义

王丽丽¹(), 王旭燕², 张培², 韩明明¹, 张静³, 赵明欣⁴

1 保定市第二中心医院输血科（邮编072750）
2 中国人民解放军陆军第八十二集团军医院耳鼻喉科
3 保定市第五医院耳鼻喉科
4 定州市人民医院耳鼻喉科

收稿日期:2024-12-02 修回日期:2025-01-09 出版日期:2025-03-15 发布日期:2025-03-31
作者简介:王丽丽（1988），女，主管技师，主要从事输血及医学检验方面研究。E-mail：645919823@qq.com
基金资助:
保定市科技计划项目(2141ZF163)

Expression and clinical significance of CLDN6, TRIM59 and CMTM6 in nasopharyngeal carcinoma

WANG Lili¹(), WANG Xuyan², ZHANG Pei², HAN Mingming¹, ZHANG Jing³, ZHAO Mingxin⁴

1 Department of Blood Transfusion, Baoding Second Central Hospital, Baoding 072750, China
2 Department of Otolaryngology, 82nd Army Hospital of the Chinese People's Liberation Army
3 Department of Otolaryngology, the Fifth Hospital of Baoding
4 Department of Otolaryngology, Dingzhou People's Hospital

Received:2024-12-02 Revised:2025-01-09 Published:2025-03-15 Online:2025-03-31

王丽丽, 王旭燕, 张培, 韩明明, 张静, 赵明欣. CLDN6、TRIM59、CMTM6在鼻咽癌组织中的表达及临床意义[J]. 天津医药, 2025, 53(3): 272-276.

WANG Lili, WANG Xuyan, ZHANG Pei, HAN Mingming, ZHANG Jing, ZHAO Mingxin. Expression and clinical significance of CLDN6, TRIM59 and CMTM6 in nasopharyngeal carcinoma[J]. Tianjin Medical Journal, 2025, 53(3): 272-276.

摘要/Abstract

摘要：

目的探究紧密连接蛋白6（CLDN6）、三结构域蛋白59（TRIM59）、趋化素样因子超家族6（CMTM6）在鼻咽癌（NPC）组织中的表达及临床意义。方法选取135例NPC患者为研究对象，收集所有患者的癌组织（观察组）及癌旁组织（对照组）。所有患者均进行3年随访。根据随访结果将93例生存患者作为生存组，42例死亡患者作为死亡组。采用荧光定量PCR法测定组织CLDN6、TRIM59、CMTM6 mRNA表达；多因素Cox回归分析NPC患者发生死亡的影响因素；Kaplan-Meier法分析NPC患者组织中CLDN6、TRIM59、CMTM6表达与患者预后的关系。结果与对照组相比，观察组组织CLDN6、TRIM59、CMTM6 mRNA表达均升高（P<0.05）。生存组与死亡组组患者的年龄、性别、体质量指数、TNM分期、骨转移、吸烟史、饮酒史、高血压史相比差异无统计学意义。与生存组相比，死亡组患者的NPC家族史的占比以及癌组织CLDN6、TRIM59、CMTM6 mRNA表达均升高（P<0.05）；多因素Cox回归分析显示癌组织CLDN6、TRIM59、CMTM6水平升高为NPC患者发生死亡的危险因素（P<0.05）；根据癌组织中CLDN6、TRIM59、CMTM6 mRNA表达的平均值将患者划分为低表达组和高表达组，癌组织CLDN6、TRIM59、CMTM6 mRNA高表达组3年生存率明显低于低表达组（P<0.05）。结论 NPC组织中CLDN6、TRIM59、CMTM6 mRNA表达均明显提高，其水平升高为NPC患者发生死亡的危险因素，三者表达与患者预后相关。

关键词: 鼻咽癌, 紧密连接蛋白6, 三结构域蛋白59, 趋化素样因子超家族6

Abstract:

Objective To investigate the expression and clinical significance of Claudin-6 (CLDN6), tripartite motif-containing protein 59 (TRIM59) and chemokine-like factor-like MARVEL transmembrane domain containing member 6 (CMTM6) in nasopharyngeal carcinoma (NPC) tissue. Methods A total of 135 NPC patients were selected as the study objects, and cancer tissue (observation group) and para-cancer tissue (control group) of all patients were collected. All patients were followed up for 3 years. According to the follow-up results, 93 surviving patients were included in the survival group and 42 dead patients were included in the death group. The mRNA expressions of CLDN6, TRIM59 and CMTM6 were determined by fluorescence quantitative PCR. Multivariate Cox regression was used to analyze the influencing factors of death in NPC patients. Kaplan-Meier method was used to analyze the relationship between the expression levels of CLDN6, TRIM59, CMTM6 and the prognosis of NPC patients. Results Compared with the control group, mRNA expressions of CLDN6, TRIM59 and CMTM6 were increased in the observation group (P<0.05). There were no significant differences in age, sex, body mass index, TNM stage, bone metastasis, smoking history, drinking history and hypertension history between the survival group and the death group. Compared with the survival group, the proportion of NPC family history and the mRNA expression of CLDN6, TRIM59 and CMTM6 in cancer tissue were increased in the death group (P < 0.05). Multivariate Cox regression analysis showed that the increased levels of CLDN6, TRIM59 and CMTM6 in cancer tissue were influential factors for death of NPC patients (P<0.05). According to the mean expression levels of CLDN6, TRIM59 and CMTM6 mRNA in cancer tissue, patients were divided into the low expression group and the high expression group. The 3-year survival rate of the high expression group was significantly lower than that of the low expression group (P<0.05). Conclusion The mRNA expressions of CLDN6, TRIM59 and CMTM6 in NPC tissue are significantly increased, which is a risk factor for death in NPC patients, and the mRNA expressions of CLDN6, TRIM59 and CMTM6 are correlated with the prognosis of patients.

Key words: nasopharyngeal carcinoma, tight junction protein Claudin-6, tripartite motif-containing protein 59, chemokine like factor superfamily 6

中图分类号:

R739.63

图/表 8

表1 观察组和对照组组织CLDN6、TRIM59、CMTM6 mRNA表达水平比较（n=135，$\bar{x} \pm s$）

Tab.1 Comparison of CLDN6, TRIM59 and CMTM6 expression levels between the observation group and the control group

组别	CLDN6	TRIM59	CMTM6
对照组	1.03±0.34	1.04±0.31	1.06±0.36
观察组	1.49±0.42	1.56±0.48	1.77±0.55
t	10.019^＊＊	10.801^＊＊	12.616^＊＊

表2 2组临床资料比较

Tab.2 Comparison of clinical data between the two groups

组别	n	年龄/ 岁	性别（男/女）	BMI/ （kg/m²）	TNM分期（Ⅰ~Ⅱ/Ⅲ~Ⅳ）
生存组	93	52.11±5.67	68/25	22.15±3.28	52/41
死亡组	42	52.83±5.84	29/13	22.09±3.24	16/26
t或χ²		0.682	0.237	0.115	3.675
组别	骨转移（是/否）	吸烟史（有/无）	饮酒史（有/无）	高血压（有/无）	NPC家族史（有/无）
生存组	19/74	51/42	51/42	39/54	23/70
死亡组	11/31	19/23	19/23	14/28	18/24
χ²	0.555	1.068	1.068	0.898	4.495^＊

表3 生存组和死亡组癌组织CLDN6、TRIM59、CMTM6 mRNA表达水平比较（$\bar{x} \pm s$）

Tab.3 Comparison of CLDN6, TRIM59 and CMTM6 mRNA expression levels in cancer tissue between the death group and the survival group

组别	n	CLDN6	TRIM59	CMTM6
生存组	93	1.32±0.36	1.38±0.37	1.59±0.49
死亡组	42	1.86±0.54	1.96±0.62	2.18±0.67
t		5.988^＊＊	5.765^＊＊	5.792^＊＊

表4 多因素Cox回归分析NPC患者发生死亡的影响因素

Tab.4 Multivariate Cox regression analysis of factors influencing death in NPC patients

指标	β	SE	Wald χ²	P	OR	95%CI
NPC家族史	0.675	0.361	3.496	0.062	1.964	0.968~3.985
CLDN6	0.729	0.338	4.658	0.031	2.074	1.069~4.023
TRIM59	0.667	0.319	4.369	0.037	1.948	1.042~3.640
CMTM6	0.674	0.307	4.827	0.028	1.963	1.075~3.583

表5 癌组织CLDN6、TRIM59、CMTM6表达与NPC患者预后的关系 [例（%）]

Tab.5 Relationship between the expression of CLDN6, TRIM59 and CMTM6 in cancer tissue and the prognosis of NPC patients

组别	n	3年生存	Log rank χ²
CLDN6低表达组	69	55（79.71）	7.711^＊＊
CLDN6高表达组	66	38（57.58）	7.711^＊＊
TRIM59低表达组	67	53（79.10）	6.477^＊
TRIM59高表达组	68	40（58.82）	6.477^＊
CMTM6低表达组	70	54（77.14）	4.621^＊
CMTM6高表达组	65	39（60.00）	4.621^＊

图1 CLDN6不同表达水平NPC患者的累积生存曲线

Fig.1 Cumulative survival curves of NPC patients with different expression levels of CLDN6

图2 TRIM59不同表达水平NPC患者的累积生存曲线

Fig.2 Cumulative survival curves of NPC patients with different TRIM59 expression levels

图3 CMTM6不同表达水平NPC患者的累积生存曲线

Fig.3 Cumulative survival curves of NPC patients with different expression levels of CMTM6

参考文献 19

[1]	TANG L L, CHEN Y P, CHEN C B, et al. The Chinese Society of Clinical Oncology(CSCO)clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma[J]. Cancer Commun(Lond), 2021, 41(11):1195-1227. doi:10.1002/cac2.12218.
[2]	吴倩, 王意, 陈念, 等. 诱导化疗对鼻咽癌患者免疫功能及炎症指标的影响[J]. 天津医药, 2024, 52(4):397-402.
	WU Q, WANG Y, CHEN N, et al. Effect of induction chemotherapy on immune function and inflammatory indicators in patients with nasopharyngeal carcinoma[J]. Tianjin Med J, 2024, 52(4):397-402. doi:10.11958/20230792.
[3]	LI S, WAN X, DENG Y Q, et al. Predicting prognosis of nasopharyngeal carcinoma based on deep learning: peritumoral region should be valued[J]. Cancer Imaging, 2023, 23(1):14. doi:10.1186/s40644-023-00530-5.
[4]	JIN Q, QI D, ZHANG M, et al. CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation[J]. Cell Mol Biol Lett, 2024, 29(1):112. doi:10.1186/s11658-024-00629-y.
[5]	LIU T, JIANG L, BAI Q, et al. CLDN6 suppresses migration and invasion of MCF-7 and SKBR-3 breast cancer cells by blocking the SMAD/Snail/MMP-2/9 axis[J]. Bull Exp Biol Med, 2023, 175(3):376-381. doi:10.1007/s10517-023-05871-6.
[6]	王静怡, 马晓林. E3泛素连接酶三结构域蛋白59对非小细胞肺癌细胞增殖和侵袭的影响[J]. 解剖学研究, 2024, 46(2):139-144.
	WANG J Y, MA X L. Effects of E3 ubiquitin ligase TRIM59 on proliferation and invasion of non-small cell lung cancer cells[J]. Anatomy Research, 2024, 46(2):139-144. doi:10.20021/j.cnki.1671-0770.2024.02.08.
[7]	WANG H, LOU J, LIU H, et al. TRIM59 deficiency promotes M1 macrophage activation and inhibits colorectal cancer through the STAT1 signaling pathway[J]. Sci Rep, 2024, 14(1):16081. doi:10.1038/s41598-024-66388-0.
[8]	XING F, GAO H, CHEN G, et al. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer[J]. Mol Cancer, 2023, 22(1):6. doi:10.1186/s12943-023-01716-y.
[9]	LANG J, HU C, LU T, et al. Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives[J]. Cancer Manag Res, 2019, 11:6365-6376. doi:10.2147/CMAR.S197544.
[10]	GIHBID A, TAWFIQ N, BENCHAKROUN N, et al. Epidemiological,clinicopathological and prognosis features of moroccan patients with nasopharyngeal carcinoma[J]. Asian Pac J Cancer Prev, 2023, 24(5):1477-1486. doi:10.31557/APJCP.2023.24.5.1477.
[11]	ITO Y, TAKASAWA A, TAKASAWA K, et al. Aberrant expression of claudin-6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma[J]. Cancer Sci, 2022, 113(4):1519-1530. doi:10.1111/cas.15284.
[12]	DONG Y, XU W, QI D, et al. CLDN6 inhibits colorectal cancer proliferation dependent on restraining p53 ubiquitination via ZO-1/PTEN axis[J]. Cell Signal, 2023, 112:110930. doi:10.1016/j.cellsig.2023.110930.
[13]	栾婕, 刘霞, 李凤月, 等. 子宫内膜癌组织中紧密连接蛋白6、紧密连接蛋白9的表达及临床意义[J]. 中国性科学, 2022, 31(12):80-84.
	LUAN J, LIU X, LI F Y, et al. Expression and clinical significance of CLDN6 and CLDN9 in endometrial cancer[J]. Chinese Journal of Human Sexuality, 2022, 31(12):80-84. doi:10.3969/j.issn.1672-1993.2022.12.020.
[14]	FENG X, YANG G, ZHANG L, et al. TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer(CRC)cells' killing[J]. Invest New Drugs, 2022, 40(6):1244-1253. doi:10.1007/s10637-022-01306-7.
[15]	YANG W, CUI X, SUN D, et al. POU5F1 promotes the proliferation,migration,and invasion of gastric cancer cells by reducing the ubiquitination level of TRAF6[J]. Cell Death Dis, 2023, 14(12):802. doi:10.1038/s41419-023-06332-8.
[16]	王文忠, 周兰柱, 孙哲, 等. 下调三结构域蛋白59(TRIM59)阻断NF-κB信号通路抑制人鼻咽癌细胞的侵袭和迁移[J]. 细胞与分子免疫学杂志, 2022, 38(5):419-424.
	WANG W Z, ZHOU L Z, SUN Z, et al. Down-regulation of tripartite motif containing 59(TRIM59)blocks the NF-κB signaling pathway and inhibits the invasion and migration of nasopharyngeal carcinoma cells[J]. Chinese Journal of Cellular and Molecular Immunology, 2022, 38(5):419-424.doi:10.13423/j.cnki.cjcmi.009432.
[17]	杜姗姗, 叶双, 解龙川, 等. miR-124-3p. 2通过CMTM6调控口腔鳞状细胞癌细胞凋亡、铁死亡的机制研究[J]. 河北医科大学学报, 2023, 44(3):252-258,278.
	DU S S, YE S, XIE L C, et al. Study on the mechanism of miR-124-3p.2 regulating apoptosis and ferroptosis of oral squamous cell carcinoma cells by CMTM6[J]. Journal of Hebei Medical University, 2023, 44(3):252-258,278. doi:10.3969/j.issn.1007-3205.2023.03.002.
[18]	武川军, 彭丽娜, 冯志星, 等. 喉鳞状细胞癌组织中SEPT2、CMTM6表达及其与化疗敏感性的关系[J]. 国际检验医学杂志, 2023, 44(9):1075-1079.
	WU C J, PENG L N, FENG Z X, et al. Expression of SEPT2 and CMTM6 in laryngeal squamous cell carcinoma tissues and its relationship with chemotherapy sensitivity[J]. Int J Lab Med, 2023, 44(9):1075-1079. doi:10.3969/j.issn.1673-4130.2023.09.011.
[19]	谢刚, 成婧, 张俊萍. 趋化素样因子超家族成员在肿瘤中的研究进展[J]. 中国肺癌杂志, 2023, 26(1):46-51.
	XIE G, CHENG J, ZHANG J P, et al. Advances in the study of chemokine-like factor superfamily members in tumors[J]. Chin J Lung Cancer, 2023, 26(1):46-51. doi:10.3779/j.issn.1009-3419.2023.106.01.

CLDN6、TRIM59、CMTM6在鼻咽癌组织中的表达及临床意义

Expression and clinical significance of CLDN6, TRIM59 and CMTM6 in nasopharyngeal carcinoma

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 8

参考文献 19

相关文章 5

编辑推荐

Metrics

本文评价

[1]	吴倩, 王意, 陈念, 周凯, 田昕, 徐晖, 苟小霞. 诱导化疗对鼻咽癌患者免疫功能及炎症指标的影响[J]. 天津医药, 2024, 52(4): 397-402.
[2]	刘玉智, 门剑龙, 李杨. 基于基因芯片探索鼻咽癌的分子靶标[J]. 天津医药, 2018, 46(6): 610-614.
[3]	林碧华 1，陈婧 2，郭春连 3，余海波 4，张鑫 5，周克元 1,5. 鼻咽癌肿瘤干细胞高表达SOD2可对抗顺铂的杀伤作用[J]. 天津医药, 2015, 43(6): 577-580.
[4]	涂英华. MTA1沉默抑制鼻咽癌侵袭能力的体外研究[J]. , 2014, 42(4): 309-311 .
[5]	费新雄. 复发苦参注射液配合同期放化疗治疗局部晚期鼻咽癌的临床观察[J]. , 2012, 40(12): 0-0 .